The establishment of the method which detects the minimal residual leukemic cells in acute myelogenous patients in remisson and predicts the patients prognosis.

建立了急性髓系缓解期患者微量残留白血病细胞检测及预测患者预后的方法。

• 批准号: 09672352
• 负责人: NARA Nobuo
• 金额: $ 2.05万
• 依托单位: Tokyo Medical and Dental University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09672352/
• 关键词: acute myelogenous leukemia; leukemic cells; leukemic balst progenitors; cytokines; WT-1 gene; 急性白血病; 白血病コロニー; 免疫グロブリン重鎖遺伝子; T細胞レセプター遺伝子

Acute myelogenous leukemia (AML) is highly lethal malignant hemopathy. To cure AML patients, malignant leukemic cells should be completely purged from the patients. Most of AML can achieve complete remission by intensive chemotherapy and/or bone marrow transplantation. Some of them, however, suffer from the relapse of AML.The major issue in leukemia therapy is how to detect the residual leukemic cells in patients and how to eradicate such residual leukemic cells.To predict the clinical outcome of AML patients, we have studied the biological properties of leukemic blast progenitors and the gene expression of WT-1 mRNA.The proliferation of leukemic cells is supported by a small subpopulation of leukemic blast progenitors with self-renewal capacity. The self-renewal capacity has been shown to significantly correlate with the patients prognosis. WT-1 gene was expressed in 22 of 24 patients studied. The expression level of WT-l mRNA, however, was not correlated with either the proliferation activity of leukemic or clinical outcome of AML patients.Further studies are necessary to find any marker that can highly predict the clinical prognosis of AML patients and to establish optimal treatment protocol tailored for each AML patient.

急性髓性白血病（AML）是一种高度致命的恶性血液病。为了治愈AML患者，应将患者体内的恶性白血病细胞彻底清除。大多数AML可以通过强化化疗和/或骨髓移植达到完全缓解。然而，其中一些人的AML会复发。白血病治疗的主要问题是如何检测患者体内残留的白血病细胞以及如何根除这些残留的白血病细胞。为了预测AML患者的临床结果，我们研究了白血病原始细胞的生物学特性和 WT-1 mRNA 的基因表达。白血病细胞的增殖是由一小部分白血病原始细胞亚群支持的，其中自我更新能力。自我更新能力已被证明与患者的预后显着相关。在所研究的 24 名患者中，有 22 名患者表达了 WT-1 基因。然而，WT-1 mRNA的表达水平与白血病的增殖活性或AML患者的临床结果均不相关。需要进一步的研究来寻找任何能够高度预测AML患者临床预后的标记物并建立最佳的标记物。为每位 AML 患者量身定制治疗方案。

项目成果

Saito K,Nakamura Y,Waga K,Hirota K,Inoue F,Enokihara H,Nara N and Furusawa S: "Mature and immature myeloid cells decrease the granulocyte colony-stimulating factor level by absorption of granulocyte colony-stimulating factor." International Journal of Hem

Saito K、Nakamura Y、Waga K、Hirota K、Inoue F、Enokihara H、Nara N 和 Furusawa S：“成熟和未成熟的骨髓细胞通过吸收粒细胞集落刺激因子来降低粒细胞集落刺激因子水平。”

Saito K, Nakamura Y, Waga K, Hirota K, Inoue F, Enokihara H, Nara N and Furusawa S: "Mature and immature myeloid cells decrease the granulocyte colony-stimulating factor level by absorption of granulocyte colony-stimulating factor." International Journal

Saito K、Nakamura Y、Waga K、Hirota K、Inoue F、Enokihara H、Nara N 和 Furusawa S：“成熟和未成熟的骨髓细胞通过吸收粒细胞集落刺激因子来降低粒细胞集落刺激因子水平。”

Tohda S,Maruyama M,and Nara N: "Molecular typing of methicillin-resistant staphylococcus aureus by polymerase chain reaction: distribution of the typed strains in hospitals." Internal Medicine. 36-10. 694-699 (1997)

Tohda S、Maruyama M 和 Nara N：“通过聚合酶链反应对耐甲氧西林金黄色葡萄球菌进行分子分型：分型菌株在医院中的分布。”

Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K, Tanikawa S: "Effect of vesnarinone,a quinolinone derivative,on the growth of leukemic blasts in acute myelogenous leukemia." Experimental Hematology. 25・3. 199-204 (1997)

Nara N、Kurokawa H、Tohda S、Tomiyama J、Nagata K、Tanikawa S：“喹啉酮衍生物 vesnarinone 对急性髓性白血病中白血病细胞生长的影响 25・3。” 1997）

Tohda S,and Nara N: "Phosphorylation of signaling proteins in factor-independent myeloid leukemia cell lines." International Journal of Oncology. 11. 843-847 (1997)

Tohda S 和 Nara N：“因子依赖性骨髓白血病细胞系中信号蛋白的磷酸化。”